People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| InSitu Biologics, Inc | — | Biotechnology | Series A | $13.9M | $10.7M | 2020 |
| PolyRemedy Inc | — | Other Health Care | Series A | $13.7M | $10.9M | 2009 |
| StrokeDx, Inc. | — | Other Health Care | Series A | $6.0M | $21.6M | 2024 |
| Sift Biosciences, Inc. | — | Biotechnology | Seed | $3.8M | $8.4M | 2025 |
| Coladka, Inc. | — | Other | Pre-Seed | $1.0M | $20.8M | 2019 |
Kevin Barrett at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Barrett on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Greeley | 1 | 15 |
| Annette Campbell-White | 1 | 11 |
| Buzz Benson | 1 | 8 |
| Robert Wilson | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| Stephen Shapiro | 1 | 6 |
| Dennis Condon | 1 | 5 |
| Douglas Roeder | 1 | 5 |
| Jeffrey Jones | 1 | 5 |
| Charles Liamos | 1 | 4 |
| Kevin Connors | 1 | 4 |
| Daniel Eckert | 1 | 3 |
| James Knapp | 1 | 3 |
| Gary Restani | 1 | 3 |
| Thomas Rodgers | 1 | 2 |
| Kevin Bassett | 1 | 2 |
| Shane Shahrestani | 1 | 1 |
| Andrew Schenck | 1 | 1 |
| David Richard | 1 | 1 |
| Charlie Liamos | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.